Amedisys AMED reports its Q2 EPS at $1.13, falling short of the consensus of $1.15. AMED’s Q2 revenue came in at $422.3 million versus the estimates of $421.26 million.
AMED’s shares lost 2.65% to $26.08 in after-hours trading.
Read more from Benzinga's Company news.
See Some of the Top Moving Indexes Here.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in